In patients with non-small cell lung cancer, certain comorbidities impact survival
the ONA take:
According to a new study published in the journal Lung, researchers have found that certain comorbidities in patients with non-small cell lung cancer (NSCLC) significantly negatively impact survival. For the study, researchers sought to investigate the negative prognostic factor of individual comorbidities in patients with primary lung cancer. They identified 10,378 patients who were diagnosed with NSCLC between 2009 and 2011. Results showed that patients with NSCLC and cardiovascular comorbidity have a 30% increased mortality rate (HR = 1.30; 95% CI: 1.13 - 1.49) compared with those without comorbidity. In addition, patients with diabetes (HR = 1.19; 95% CI: 1.02 - 1.39), cerebrovascular disorders (HR = 1.18; 95% CI: 1.05 - 1.33), and chronic obstructive pulmonary disease (COPD) (HR = 1.20; 95% CI: 1.10 - 1.39) have an approximately 20% increased mortality rate compared with those without comorbidity.
Primary lung cancer is one of the most frequently occurring types of cancer, and morbidity has been shown to negatively impact survival in patients with lung cancer. This study shows that comorbid cardiovascular disease, diabetes, cerebrovascular disorders, and COPD individually increase the death rate of patients by 20% to 30%.
A family member serves as a caregiver for a patient with cancer.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|